Not applicableStudy completedNCT02916017What this trial is testingHUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitisWho this might be right forUveitis AbbVie 259
Early research (Phase 1)Not Yet RecruitingNCT07427628What this trial is testingA Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious UveitisWho this might be right forNon Infectious Uveitis Quan Dong Nguyen 18
Testing effectiveness (Phase 2)Study completedNCT04706741What this trial is testingA Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior UveitisWho this might be right forUveitis ACELYRIN Inc. 7
Large-scale testing (Phase 3)Ended earlyNCT02258854What this trial is testingAn Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety DataWho this might be right forUveitis XOMA (US) LLC 69
Large-scale testing (Phase 3)Ended earlyNCT01684345What this trial is testingSafety and Efficacy Study of Gevokizumab to Treat Active Non-infectious UveitisWho this might be right forUveitis XOMA (US) LLC 200
Large-scale testing (Phase 3)Study completedNCT00404612What this trial is testingLX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-UveitisWho this might be right forUveitis, PosteriorUveitis, IntermediatePanuveitis Lux Biosciences, Inc. 218
Post-approval studies (Phase 4)Study completedNCT05414201What this trial is testingAssess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-UveitisWho this might be right forNon-infectious Intermediate Posterior- or Pan-uveitis AbbVie 87
Testing effectiveness (Phase 2)Ended earlyNCT05953688What this trial is testingPOC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUWho this might be right forUveitis Posterior Non-InfectiousUveitis, IntermediateNoninfectious Panuveitis Alumis Inc 36
Large-scale testing (Phase 3)Study completedNCT00404742What this trial is testingLX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-UveitisWho this might be right forUveitis, PosteriorUveitis, IntermediatePanuveitis Lux Biosciences, Inc. 232
Testing effectiveness (Phase 2)Study completedNCT01900431What this trial is testingPhase II Study to Analyze Sarilumab in Non-Infectious UveitisWho this might be right forUveitis Sanofi 58
Large-scale testing (Phase 3)Study completedNCT01148225What this trial is testingThe Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitisWho this might be right forUveitis AbbVie 424
Testing effectiveness (Phase 2)UnknownNCT01717170What this trial is testingStudy of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS StudyWho this might be right forIntermediate UveitisPosterior UveitisPan-uveitis University of Nebraska 36
Testing effectiveness (Phase 2)Ended earlyNCT05384249What this trial is testingPhase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitisWho this might be right forUveitis ACELYRIN Inc. 96
Testing effectiveness (Phase 2)Study completedNCT02931175What this trial is testingACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)Who this might be right forUveitis Quan Dong Nguyen 28
Large-scale testing (Phase 3)Ended earlyNCT01747538What this trial is testingSafety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic TreatmentWho this might be right forUveitis XOMA (US) LLC 281
Testing effectiveness (Phase 2)Study completedNCT05523765What this trial is testingBrepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisWho this might be right forNon-infectious Intermediate UveitisNon-infectious Posterior UveitisNon-infectious Pan Uveitis Priovant Therapeutics, Inc. 26